1. Home
  2. PLSM vs CVM Comparison

PLSM vs CVM Comparison

Compare PLSM & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLSM

Pulsenmore Ltd. Ordinary Shares

N/A

Current Price

$6.03

Market Cap

25.0M

Sector

Health Care

ML Signal

N/A

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$1.05

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSM
CVM
Founded
2014
1983
Country
Israel
United States
Employees
63
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.0M
21.4M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PLSM
CVM
Price
$6.03
$1.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.8M
357.5K
Earning Date
03-30-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.45
52 Week Low
$3.00
$0.89
52 Week High
$12.97
$13.48

Technical Indicators

Market Signals
Indicator
PLSM
CVM
Relative Strength Index (RSI) 69.23 34.15
Support Level $3.49 $0.94
Resistance Level $6.64 $1.59
Average True Range (ATR) 0.88 0.11
MACD 0.22 0.03
Stochastic Oscillator 27.69 17.31

Price Performance

Historical Comparison
PLSM
CVM

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: